Are there any Skyrizi (risankizumab) biosimilar Phase 3 trials planned for 2026?
Based on the information provided here, there are no specific, dated details about Skyrizi biosimilar Phase 3 trial timelines for 2026 that can be confirmed.
Which biosimilar companies are running (or preparing) Phase 3 studies for Skyrizi?
No company names, study identifiers (e.g., NCT numbers), or trial start/completion dates for Skyrizi biosimilars are included in the supplied information, so I can’t verify which programs are in Phase 3 or targeting a 2026 milestone.
What would “Phase 3 in 2026” typically mean for patients and approvals?
A Phase 3 trial date around 2026 would usually relate to when companies expect to complete key efficacy/safety data collection that regulators use for marketing approval. The exact meaning depends on the study’s start date, duration, and whether results are filed as the trial concludes—factors that aren’t provided in your question.
Where can you verify Skyrizi biosimilar Phase 3 trial start dates and timelines?
To check whether any Skyrizi biosimilars have Phase 3 trials that involve 2026 timelines, you typically need to look up each product in clinical trial registries (for example, ClinicalTrials.gov) and match trial status, estimated enrollment, and completion dates to 2026.
If you want, I can narrow it down quickly
Share any of the following, and I can tell you whether it lines up with a 2026 Phase 3 timeline:
- A biosimilar brand name or sponsor name
- A ClinicalTrials.gov link or NCT number
- The country/region you care about (US, EU, UK, etc.)
Sources: none provided in the prompt (and no DrugPatentWatch.com details were supplied to cite).